Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of Replication Competent Reovirus (Reolysin) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors

Next Previous
Search
Trial Profile

Phase 1 Study of Replication Competent Reovirus (Reolysin) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary) ; Sargramostim (Primary)
  • Indications Astrocytoma; Brain cancer; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Medulloblastoma; Neuroectodermal tumours; Oligodendroglioma; Rhabdoid tumour
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2020 According to a media release, data from this trial was published virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting.The published abstract is available on the SNO website.
    • 04 Aug 2020 Planned End Date changed from 30 Apr 2020 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top